Compare Charles Schwab Corporation Common Stock (SCHW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs 10X Genomics Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.81B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 21.6× 10X Genomics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.2% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SCHW | TXG | |
|---|---|---|
Market Cap | $184.81B | $8.55B |
Sector | Financials | Health |
52-Week High | $113.65 | $67.29 |
52-Week Low | $85.35 | $11.34 |
Dividend Yield | 1.2% | — |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $106.87, down 2.21% today, as technical indicators signal bearish momentum with price near key support at $106. Fundamentally, the company shows strength with Q2 2026 EPS beating estimates at $1.62 versus $1.56 expected, and revenue growth accelerating to $23.92B in 2025. Analyst sentiment remains positive with 57% buy ratings and a $122.14 consensus target, representing 14% upside potential from current levels.
The outlook remains favorable given strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures from Vanguard's Altruist acquisition present risks. With robust cash flow generation and improving debt metrics, SCHW offers value for long-term investors despite current bearish technical signals.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
